Ovarian Cancer Research
The program in Gynecologic Medical Oncology (Drs. Stephen Cannistra, Panagiotis Konstantinopoulos and Dimitrios Spentzos) is largely involved with clinical and translational research activities.
The clinical research efforts involve developing new treatments for patients with high risk ovarian cancer, including novel first line chemotherapy regimens as well as innovative approaches to treatment of relapsed disease. Many clinical trials are investigator-initiated and include upfront combination chemotherapy regimens, consolidative oral chemotherapy, as well as use of novel phase I agents such as oral angiogenesis inhibitors for patients with early relapse.
The translational research efforts are centered around use of our ovarian cancer tissue bank and correlative clinical database. The program is currently using this resource to define gene expression profiles predictive of chemotherapy resistance and prognostic of poor survival. These activities have resulted in a recent Dana-Farber/Harvard Cancer Center (DF/HCC) Ovarian SPORE award, of which the program is a major contributor.
The clinical research efforts involve developing new treatments for patients with high risk ovarian cancer, including novel first line chemotherapy regimens as well as innovative approaches to treatment of relapsed disease. Many clinical trials are investigator-initiated and include upfront combination chemotherapy regimens, consolidative oral chemotherapy, as well as use of novel phase I agents such as oral angiogenesis inhibitors for patients with early relapse.
The translational research efforts are centered around use of our ovarian cancer tissue bank and correlative clinical database. The program is currently using this resource to define gene expression profiles predictive of chemotherapy resistance and prognostic of poor survival. These activities have resulted in a recent Dana-Farber/Harvard Cancer Center (DF/HCC) Ovarian SPORE award, of which the program is a major contributor.